{"id":745125,"date":"2015-09-08T07:30:00","date_gmt":"2015-09-08T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/"},"modified":"2025-11-07T01:24:59","modified_gmt":"2025-11-07T06:24:59","slug":"merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/","title":{"rendered":"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea"},"content":{"rendered":"<p class=\"bwalignc\">       First Product from Global Partnership to Deliver High-Quality        Biosimilars to Help Meet Needs of Patients and Healthcare Systems        Worldwide     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS\u2122<br \/>\n      (etanercept), a biosimilar of the immunology medicine Enbrel, by the<br \/>\n      Ministry of Food and Drug Safety (MFDS) in Korea. BRENZYS is indicated<br \/>\n      for the treatment of rheumatoid arthritis, psoriatic arthritis, axial<br \/>\n      spondyloarthritis (non-radiographic axial spondyloarthritis and<br \/>\n      ankylosing spondylitis) and psoriasis in adult patients (age 18 years<br \/>\n      and older).\n    <\/p>\n<p>\n      The approval of BRENZYS in Korea represents the first product approval<br \/>\n      under Merck\u2019s collaboration with Samsung Bioepis, which is designed to<br \/>\n      offer high-quality biosimilar alternatives to existing biologic<br \/>\n      medicines to help address patient and healthcare system needs worldwide.<br \/>\n      Merck plans to launch BRENZYS in South Korea by the end of this year or<br \/>\n      early next year.\n    <\/p>\n<p>\n      \u201cWe are very excited to receive this first regulatory approval of a<br \/>\n      biosimilar product resulting from our late-stage development pipeline,\u201d<br \/>\n      said Christopher Hansung Ko, CEO of Samsung Bioepis. \u201cThe approval of<br \/>\n      BRENZYS in Korea is especially gratifying, and underscores our<br \/>\n      commitment to advancing healthcare through innovation and groundbreaking<br \/>\n      technology. We look forward to building on this progress in our<br \/>\n      collaboration with Merck.\u201d\n    <\/p>\n<p>\n      \u201cThe approval of BRENZYS in Korea is a key milestone in Merck\u2019s<br \/>\n      longstanding commitment to improving access to important medicines,\u201d<br \/>\n      said Dora Bibila, general manager, Merck Biosimilars. \u201cWe are excited by<br \/>\n      the opportunity to deliver on the promise of biosimilars overall \u2013 and<br \/>\n      on the promise of BRENZYS \u2013 by combining Merck\u2019s deep global customer<br \/>\n      expertise with the extensive development and manufacturing capabilities<br \/>\n      of Samsung Bioepis.\u201d\n    <\/p>\n<p>\n      Merck\u2019s launch of BRENZYS will include comprehensive education and<br \/>\n      support services for healthcare professionals, patients and their<br \/>\n      caregivers, including biosimilars education, disease education, and<br \/>\n      reimbursement and access support.\n    <\/p>\n<p>\n      The approval of BRENZYS in Korea was supported by rigorous analytical<br \/>\n      structural and functional testing, as well as a Phase 1 crossover<br \/>\n      pharmacokinetics study and a Phase 3 clinical study comparing BRENZYS to<br \/>\n      the originator medicine.\n    <\/p>\n<p>\n      <b>About the Merck and Samsung Bioepis collaboration<\/b>\n    <\/p>\n<p>\n      Merck and Samsung Bioepis announced in February 2013 a collaboration to<br \/>\n      develop and commercialize in certain partnered territories multiple<br \/>\n      biosimilar candidates. In February 2014, the two companies expanded the<br \/>\n      collaboration to include MK-1293, an insulin glargine biosimilar<br \/>\n      candidate currently in Phase 3 clinical development for the treatment of<br \/>\n      patients with type 1 and type 2 diabetes. Under terms of the agreement,<br \/>\n      Samsung Bioepis is responsible for preclinical and clinical development,<br \/>\n      process development and manufacturing, clinical trials and regulatory<br \/>\n      registration, except for MK-1293, which Merck will continue to develop<br \/>\n      and manufacture. Merck will be responsible in its partnered territories<br \/>\n      for commercialization of all approved products resulting from the<br \/>\n      collaboration.\n    <\/p>\n<p>\n      The portfolio includes biosimilar candidates in immunology, oncology and<br \/>\n      diabetes. There are five candidates in Phase 3 development [Merck<br \/>\n      partnered territories]:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        SB4 Enbrel (etanercept) [worldwide ex-U.S.\/EU\/Japan]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB2 Remicade (infliximab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB5 Humira (adalimumab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB3 Herceptin (trastuzumab) [worldwide]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-1293 Lantus (insulin glargine) [worldwide]\n      <\/li>\n<\/ul>\n<p>\n      Additional regulatory filings for each of these five biosimilar<br \/>\n      candidates are expected to occur in the 2015-2016 timeframe.\n    <\/p>\n<p>\n      <b>About Samsung Bioepis<\/b>\n    <\/p>\n<p>\n      Samsung Bioepis was established in 2012 as part of the Samsung group.<br \/>\n      The company\u2019s mission is to produce affordable, high-quality<br \/>\n      biopharmaceutical products for diseases with high unmet medical,<br \/>\n      humanistic and economic needs. The company aims to be the world\u2019s<br \/>\n      leading pharmaceutical company with its effort for innovation and<br \/>\n      advanced technologies. Please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=www.samsungbioepis.com&amp;index=1&amp;md5=34c0392d891d7be1b8030b0a39717012\" rel=\"nofollow\">www.samsungbioepis.com<\/a><br \/>\n      for more information.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=24cd87834c77047137115470240f8411\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=0bc3abda0a33d2ba360a4feb0c0a3bb3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=4575f53857b475fb0ca39bfc09f02bc9\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=2ede72fea3b2cbc1f5016f99834ef2e0\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51176067&amp;newsitemid=20150908005550&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=2c5719fd0c81ddd955fc31d351d26632\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Robert        Consalvo,&nbsp;908-236-1127<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879<br \/>or<br \/>Samsung Bioepis<br \/>Media:<br \/>Jamyung        Cha, (82) 32-455-6137<br \/>or<br \/>Investors:<br \/>Sungjoon Park, (82)        32-455-6120     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS\u2122 (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. BRENZYS is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis) and psoriasis in adult patients (age 18 years and older). The approval of BRENZYS in Korea represents the first product approval under Merck\u2019s collaboration with Samsung Bioepis, which is designed to offer high-quality biosimilar alternatives to existing biologic medicines to help address patient and healthcare system needs worldwide. Merck plans to launch BRENZYS in South Korea by the end of this year or early next<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745125","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com\" \/>\n<meta property=\"og:description\" content=\"First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS\u2122 (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. BRENZYS is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis) and psoriasis in adult patients (age 18 years and older). The approval of BRENZYS in Korea represents the first product approval under Merck\u2019s collaboration with Samsung Bioepis, which is designed to offer high-quality biosimilar alternatives to existing biologic medicines to help address patient and healthcare system needs worldwide. Merck plans to launch BRENZYS in South Korea by the end of this year or early next\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:59+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/\",\"name\":\"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-09-08T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:24:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com","og_description":"First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS\u2122 (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. BRENZYS is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis) and psoriasis in adult patients (age 18 years and older). The approval of BRENZYS in Korea represents the first product approval under Merck\u2019s collaboration with Samsung Bioepis, which is designed to offer high-quality biosimilar alternatives to existing biologic medicines to help address patient and healthcare system needs worldwide. Merck plans to launch BRENZYS in South Korea by the end of this year or early next","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:59+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/","name":"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-09-08T07:30:00+00:00","dateModified":"2025-11-07T06:24:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150908005550r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-announce-approval-of-brenzys-etanercept-a-biosimilar-of-enbrel-in-korea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Samsung Bioepis Announce Approval of BRENZYS\u2122 (Etanercept), a Biosimilar of Enbrel, in Korea"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d2770af2-bf1a-4d31-af22-cffc6082f0ca","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/09\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/09\/1\/2264411_Samsung_Bioepis_Logo-281-29.jpg","size":"12484","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Samsung-Bioepis-Announce-Approval-of-BRENZYS-Etanercept-a-Biosimilar-of-Enbrel-in-Korea-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745125\/revisions"}],"predecessor-version":[{"id":3674606,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745125\/revisions\/3674606"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745125"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}